|
Aligos Therapeutics, Inc. (ALGS) Avaliação DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Aligos Therapeutics, Inc. (ALGS) Bundle
Seja você um investidor ou analista, esta calculadora DCF (ALGS) é o seu recurso preferido para uma avaliação precisa. Equipado com dados reais da Aligos Therapeutics, Inc., você pode ajustar as previsões e observar imediatamente os efeitos.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | 4.4 | 13.9 | 15.5 | 19.9 | 25.4 | 32.5 | 41.6 | 53.2 |
| Revenue Growth, % | 0 | 0 | 0 | 219.04 | 11.66 | 27.92 | 27.92 | 27.92 | 27.92 | 27.92 |
| EBITDA | -49.9 | -105.1 | -124.5 | -93.9 | -85.1 | -4.0 | -5.1 | -6.5 | -8.3 | -10.6 |
| EBITDA, % | 100 | 100 | -2857.15 | -675.24 | -547.74 | -20 | -20 | -20 | -20 | -20 |
| Depreciation | 2.3 | 3.3 | 3.8 | 3.7 | 3.1 | 13.2 | 16.9 | 21.6 | 27.7 | 35.4 |
| Depreciation, % | 100 | 100 | 86.67 | 26.43 | 19.76 | 66.57 | 66.57 | 66.57 | 66.57 | 66.57 |
| EBIT | -52.2 | -108.4 | -128.3 | -97.6 | -88.1 | -4.0 | -5.1 | -6.5 | -8.3 | -10.6 |
| EBIT, % | 100 | 100 | -2943.82 | -701.66 | -567.5 | -20 | -20 | -20 | -20 | -20 |
| Total Cash | 117.7 | 243.5 | 190.7 | 125.8 | 135.7 | 19.9 | 25.4 | 32.5 | 41.6 | 53.2 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | 7.9 | 10.2 | 13.0 | 16.6 | 21.3 |
| Account Receivables, % | 100 | 100 | 0 | 0 | 0 | 40 | 40 | 40 | 40 | 40 |
| Inventories | .0 | .0 | .0 | .0 | .0 | 7.9 | 10.2 | 13.0 | 16.6 | 21.3 |
| Inventories, % | 100 | 100 | 0 | 0 | 0 | 40 | 40 | 40 | 40 | 40 |
| Accounts Payable | 3.8 | 3.3 | 3.0 | 4.7 | 2.5 | 12.7 | 16.2 | 20.8 | 26.6 | 34.0 |
| Accounts Payable, % | 100 | 100 | 69.17 | 34.06 | 16.21 | 63.89 | 63.89 | 63.89 | 63.89 | 63.89 |
| Capital Expenditure | -2.8 | -2.1 | -.9 | -.9 | .0 | -1.1 | -1.4 | -1.8 | -2.3 | -2.9 |
| Capital Expenditure, % | 100 | 100 | -20.46 | -6.78 | -0.12235 | -5.47 | -5.47 | -5.47 | -5.47 | -5.47 |
| Tax Rate, % | -0.91501 | -0.91501 | -0.91501 | -0.91501 | -0.91501 | -0.91501 | -0.91501 | -0.91501 | -0.91501 | -0.91501 |
| EBITAT | -52.3 | -108.5 | -128.5 | -97.7 | -88.9 | -4.0 | -5.1 | -6.5 | -8.3 | -10.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -49.0 | -107.7 | -125.9 | -93.2 | -88.1 | 2.4 | 9.5 | 12.2 | 15.6 | 20.0 |
| WACC, % | 15.33 | 15.33 | 15.33 | 15.33 | 15.33 | 15.33 | 15.33 | 15.33 | 15.33 | 15.33 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 35.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 20 | |||||||||
| Terminal Value | 153 | |||||||||
| Present Terminal Value | 75 | |||||||||
| Enterprise Value | 111 | |||||||||
| Net Debt | -125 | |||||||||
| Equity Value | 235 | |||||||||
| Diluted Shares Outstanding, MM | 25 | |||||||||
| Equity Value Per Share | 9.47 |
What You Will Get
- Real ALGS Financials: Access historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Evaluate various scenarios to assess Aligos Therapeutics' future prospects.
- User-Friendly Design: Tailored for experts while remaining easy to navigate for newcomers.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Aligos Therapeutics, Inc. (ALGS).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to the biotech sector.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to align with Aligos Therapeutics' strategic goals.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Aligos Therapeutics, Inc. (ALGS).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for streamlined analysis.
How It Works
- Download the Template: Get instant access to the Excel-based ALGS DCF Calculator.
- Input Your Assumptions: Adjust the yellow-highlighted cells for growth rates, WACC, margins, and more.
- Instant Calculations: The model automatically updates Aligos Therapeutics’ intrinsic value.
- Test Scenarios: Simulate different assumptions to evaluate potential valuation changes.
- Analyze and Decide: Use the results to guide your investment or financial analysis.
Why Choose Aligos Therapeutics, Inc. (ALGS)?
- Innovative Solutions: Focused on developing transformative therapies for viral infections and liver diseases.
- Expert Team: Comprised of industry veterans with extensive experience in drug development.
- Robust Pipeline: Multiple clinical-stage programs targeting significant unmet medical needs.
- Strategic Partnerships: Collaborations with leading organizations to enhance research and development.
- Commitment to Patients: Dedicated to improving the lives of patients through groundbreaking science.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for assessing Aligos Therapeutics, Inc. (ALGS).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights for clients interested in Aligos Therapeutics, Inc. (ALGS).
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech companies like Aligos Therapeutics, Inc. (ALGS) are valued in the market.
What the Template Contains
- Preloaded ALGS Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.